PharmaCyte Biotech, Inc.
corporate_fare Company Profile
PharmaCyte Biotech, Inc. (NASDAQ:PMCB) is a publicly traded company in the Life Sciences sector. Wiseek has independently scored 8 items for PMCB at importance 7 or higher on its 1–10 market-impact scale. Its most recent item scored 7 or higher is dated 2026-11-11, rated 7/10. Across its 8 most recent items scored 7 or higher, the top rating is 9/10, with 7 rated 8 or above. Recent SEC coverage for PMCB spans 8-K, 10-Q, DEF 14A, PRE 14A.
Recent high-impact activity:
- PharmaCyte Sets Reverse Stock Split as Nasdaq $1 Bid Deadline Looms
- PharmaCyte Fires Auditor CBIZ, Hires Grassi Amid Material Weaknesses and Nasdaq Delisting Risk
- PharmaCyte Posts $5.1M Quarterly Loss, Flags Material Weaknesses and Nasdaq Delisting Risk
- Stockholders Approve Reverse Split Authority and Significant Equity Plan Expansion
- PharmaCyte Biotech Secures $7M Financing Amidst Nasdaq Delisting Threat & Clinical Hold
Financial Snapshot
Short Interest & Short Volume
1.19 days to coverFINRA reported short interest of 50,675 shares in PMCB as of the October 30, 2026 settlement, a 27.7% decrease from the prior period — about 1.2 days to cover at its recent average daily volume. On November 13, 2026, 34.5% of PMCB volume reported to FINRA trade-reporting facilities was marked short.
Daily short sale volume covers trades reported to FINRA trade-reporting facilities and is not the same as short interest (bi-monthly reported positions). Source: FINRA — FINRA is the owner and source of this short interest and short sale volume data; it may not be redistributed.